Indian Pharma

The market recorded sales of Rs 23,193 crore in July, with cardiac and anti-diabetic therapies posting double-digit growth and four leading segments accounting for 46.6 per cent

Indian pharma companies are expanding selectively in the US for complex products while retaining India as their manufacturing base despite Trump's tariff threat

Industry seeks AI-based submission tools and unified digital portals to accelerate approvals and compliance tracking

: Biocon Ltd on Wednesday said it has received notice of compliance approval from Canadian health regulator for its Yesintek (ustekinumab) autoinjector, indicated for the treatment of moderate to severe plaque psoriasis. The company's subsidiary in Canada has received Notice of Compliance (NOC) approval for Yesintek (ustekinumab) Autoinjector 45 mg/0.05 mL and 90 mg/mL from Health Canada, Biocon Ltd said in a regulatory filing. Health Canada previously granted NOC for Yesintek (solution for subcutaneous injection) 45 mg/0.5ml (prefilled syringe and vial) and 90 mg/ml (prefilled syringe) and Yesintek I.V. (solution for intravenous infusion) 130 mg/26 mL (5mg/mL) in October 2025, it added. The availability of the Yesintek autoinjector provides patients with an option that the originator product does not offer in Canada, the company said . The new format will allow customised treatment approaches across care settings and patient needs, it added. Biocon said Yesintek is indicated for

Biocon received approval from the European Medicines Agency (EMA) for a new drug product fill finish line for Semglee (insulin glargine) at its insulin manufacturing facility in Malaysia.

Biocon, Zydus, Dr Reddy's are among companies positioning for one of the largest biosimilar launches for cancer treatment

Lupin, Intas Pharmaceuticals, Sun Pharma, MSN Laboratories, Natco Pharma, Zydus Life Sciences and Dr Reddy's Laboratories are some of the companies, the note said, that could potentially benefit.

Once-a-day injectable antibiotic aimed at treatment beyond hospitals through outpatient centres

Going forward Cipla's management expects to pick up momentum in FY27 and aspires $1 billion revenue from the US itself.

India's pharmaceutical market grew 10.3 per cent in April, led by strong demand for anti-diabetes, cardiac and respiratory therapies

Sun Pharma's Organon deal lifts stock, but growth concerns and high debt at the acquired firm may cap upside despite synergy potential

Pharma veteran Umang Vohra to lead Advent-backed Cohance Lifesciences as chairman and CEO, succeeding Vivek Sharma amid efforts to revive growth and address regulatory challenges

Currently, more than 95 per cent of Rubicon's revenue comes from the United States (US), where the company has built a generics and specialty portfolio

Nearly six decades after its founding, Lupin is targeting its next global growth phase in the US with a strategy centred on complex generics, biosimilars and innovation

India and Uzbekistan have launched a policy-backed pharma-nutraceutical corridor to improve regulatory alignment, investment and market access for manufacturers targeting the $7-10 billion Eurasian he

The Indian pharmaceutical market posted 11% growth in February 2026, driven by strong therapy performance, while Mounjaro remained India's highest-selling drug by value for a fifth month

Novartis exits India's mass-market generics, signalling a deeper split between MNC innovation bets and domestic pharma scale

Lupin management remains confident that the India formulations business will continue to outperform IPM by 1.2-1.3 times, supported by strong sales force and pipeline of new product launches.

At the IPA summit, pharma leaders said India's 2047 ambitions depend on embedding AI, strengthening trust and accelerating innovation, as speed and quality become the sector's defining advantages

USFDA data show OAI rates for Indian pharma plants falling to 8% by 2025 even as global outcomes worsen, reflecting stronger quality systems, technology adoption and compliance culture